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Cross sectional, qualitative thematic
analysis of patient perspectives of
disease impact in juvenile idiopathic
arthritis-associated uveitis
Ethan S. Sen1,2, Michelle J. Morgan3, Rachael MacLeod4, Helen Strike1, Ann Hinchcliffe5, Andrew D. Dick2,5,6,
Brinda Muthusamy7 and Athimalaipet V. Ramanan1,2*
Abstract
Background: Chronic health conditions in children can have a significant impact on their quality of life. The aim of
this study was to explore the subjective experience of children and young people being treated for chronic, non-
infectious uveitis associated with a systemic disease such as juvenile idiopathic arthritis.
Methods: A semi-structured interview was conducted with 10 children and young people aged between 6 and 18 years
of age and their parents.
Results: Preliminary thematic analysis indicated that both the treatment and complications of the disorder have a
significant impact on the quality of life and emotional well-being of patients, not only in terms of the discomfort
experienced but also in perceptions of social isolation, anxiety and sense of injustice.
Conclusion: This study shows that themes including “impact on school”, “social factors” and “emotional reactions” are
important domains influencing health-related quality of life (HRQoL) in children with chronic uveitis. Inclusion
of questions relating to these domains should be considered in future uveitis-specific tools examining HRQoL
in these patients.
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Background
The importance of measuring health-related quality of life
(HRQoL) in children with chronic health conditions is
widely acknowledged [1, 2]. Multiple generic, organ- and
disease-specific patient-reported outcome measures
(PROMs) of HRQoL in children exist, including tools that
combine generic and specific measures [3–8]. HRQoL is
known to result from a complex interaction of physical,
social and cultural factors, with severity of illness or dis-
ability not necessarily being associated with worse
HRQoL, as exemplified by the disability paradox [3, 9, 10].
Understandably, the HRQoL of children with visual
impairment can be significantly reduced [3, 4, 6]. In recent
years, a number of vision- and disease-specific HRQoL
PROMs for children have been developed, beginning to
populate a landscape that previously was largely void of
such tools, although it is still felt that there is a lack of
instruments to measure vision-related function and QoL
in children overall [3, 4, 6–8, 11, 12]. Amongst these tools
is the Effects of Youngsters’ Eyesight on Quality of Life
Questionnaire (EYE-Q), which has been validated as a
uveitis-specific measure, both for uveitis alone, and uveitis
associated with chronic illness, such as juvenile idiopathic
arthritis (JIA) [4]. The EYE-Q comprises 19 items, includ-
ing 4 regarding QoL.
Chronic anterior uveitis (CAU), the persistent inflam-
mation of the anterior segment of the eye, is the most
frequent extra-articular manifestation of JIA. Often
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clinically silent, CAU can lead to visually-disabling com-
plications including cataracts, glaucoma, band keratopa-
thy and macular oedema, both as a result of chronic
disease activity and treatment, which can be burdensome
[13, 14]. Treatment includes topical and systemic gluco-
corticoids as well as systemic immunosuppressive
therapies, including methotrexate, and newer biological
therapies, with a move to introducing these sooner to
minimise glucocorticoid use [14, 15].
This study aims to develop an understanding of the
subjective experience of the impact of both uveitis treat-
ment and its complications on the HRQoL of children,
incorporating parent perceptions, with a view to ascer-
taining if any important additional topics are worth
considering for inclusion in future PROMs of QoL in
children with uveitis.
Methods
This cross-sectional interview study was sponsored by the
University Hospitals Bristol NHS Foundation Trust and
approved by the South West Research Ethics Committee
(Reference [11]/SW/0109, Protocol number CH/2010/
3587, IRAS project ID 61606). This study included both
child and parent perspectives, as there is often discord-
ance between the two, with the parent proxy of cognitive
and emotional reactions to various disorders differing
from child reports [1, 16]. Both the children and their par-
ents provided written informed consent/assent to partici-
pate in the study.
Ten subjects aged 6 to 18 years old and their parents
were selected by purposive sampling from the records of
the multi-disciplinary paediatric rheumatology and uveitis
clinic. The sample was stratified by age, gender and uveitis
severity in order to achieve a representative group for ana-
lysis. Two age bands were used for sampling: 6 to 12 years
and 13 to 18 years with five participants in each age band.
Five participants were male and five were female. The two
categories of disease severity (moderate and severe uveitis)
were equally represented in the sample. The severity of
the uveitis was determined by the treating ophthalmolo-
gist using the Standardisation of Uveitis Nomenclature
(SUN) anterior chamber (AC) cell grade, AC flare and vit-
reous haze together with ocular co-morbidities and the
number of systemic therapies in preceding years [17, 18].
Nine children had JIA-associated uveitis and one child
was diagnosed with Blau syndrome and uveitis. Children
under 6 years old and those with significant learning diffi-
culties were excluded due to restriction in cognitive and
verbal skills [16].
A Consultant Clinical Psychologist conducted a
30 min, audio-taped, semi-structured interview covering
six principal domains and a general section with each
participant. The six domains included: treatment re-
ceived, ocular complications, impact on school activities,
impact on out-of-school activities, social impact and
emotional reactions. The general section comprised
further open-ended questions to elicit items that either
the children or their parents felt were indicative of the
impact of the disease on the child’s life but had not been
previously covered. Whenever possible, children and
parents were interviewed separately with the interview
schedules covering the same domains but with the
wording of questions adapted to the appropriate
developmental level.
The audiotapes of the discussions were transcribed
verbatim. Responses were analysed using inductive
thematic analysis [19–21]. First the data were read care-
fully to identify meaningful units of text relevant to the
research topic. Second, units of text dealing with the
same issue were grouped together in analytic categories
and given provisional labels. Finally, the data were
reviewed to ensure that sets of data to support each label
were identified.
Results
A total of 10 children / young people were included in
this study. Three patients, at their request, were inter-
viewed together with their parents. In the remaining
seven cases, the patients and parents were interviewed
separately. The results, therefore, represent the out-
comes from 17 different interviews.
Patient demographics and disease characteristics are
shown in Table 1. As expected from the purposive
sampling strategy, males and females, and ages above
and below 12 years, were equally represented. The dur-
ation of uveitis ranged from 1.5 to over 8 years. There
was a variety of disease severity: one patient had uncom-
plicated disease controlled with topical corticosteroid
drops and subcutaneous methotrexate; other patients
had ongoing active disease, previous treatments with
four or five systemic therapies and surgery for cataracts
or glaucoma.
The study has identified multiple important themes
across the six principal domains of “impact of treat-
ment”, “complications”, “impact on school”, “impact
outside of school”, “social factors” and “emotional
reactions” (Table 2).
In the “impact of treatment” domain, the direct effects
of therapeutic interventions such as painful injections,
nausea and difficulties swallowing tablets were highlighted.
These, in turn, led to both anticipatory nausea in some
patients and avoidance behaviour in others, with negative
emotional reactions to treatment being a frequently
occurring theme:
“On some occasions it would take up to two hours to
administer the injection because he would cry and
scream and throw a general wobbly…he ended up
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developing a phobia of all things yellow because the
sharps bins were yellow and methotrexate is yellow”.
The indirect effects of receiving treatment, such as miss-
ing school for appointments and treatment were import-
ant to both children and young people. Additionally,
anxiety about perceived lack of symptom improvement
despite treatment was identified as a significant concern
by one patient:
“I can get agitated as I don’t really see it getting any
better”.
This lack of perceived improvement also exacerbated
avoidance of treatments and caused difficulties between
parents and children regarding adherence to treatment
regimes. Patterns of non-adherence followed by “nagging”
on the part of the parent were described. Unfortunately,
adjustment to medication does not necessarily follow and
some families indicated that the negative emotional reac-
tion actually increased over time:
“She has got more upset about having her injection
than she used to be”.
There were a number of themes identified in the “impact
on school” domain. Upset at missing lessons and subse-
quent anxiety was a strong theme:
“I usually miss out on the understanding of some of the
lessons because I wasn’t there for it – it makes you feel
worried because I don’t know what I am doing”.
The pressure to catch up with missed schoolwork is an
additional stress for these children, and parents are
aware that progress can be patchy, often in relation to
the child’s interests and motivation. There were also
practical issues for those experiencing visual problems
such as not being able to read the board in class, espe-
cially if placed at the rear of the classroom, or not being
able to participate fully in Physical Education (PE):
“I’m always the last one to get ready for PE and
everyone else is waiting on the carpet for me. I feel
embarrassed and lonely”.
Even when adaptations are made by the school, they
are not always successful, with young people com-
menting on laptop computers not being available at
the beginning of each school year or examinations
being printed on large sheets of paper that would not
fit onto the desk. Furthermore, young people felt that
teachers did not always remember the visual difficul-
ties they had and they were reluctant to inform or
remind teaching staff as they did not wish to appear
different from their peers:
“I don’t really tell the teachers about my medical stuff
........I don’t want to sit in another place to other
people because that can be embarrassing”.
Table 2 Themes identified across the six domains in the
semi-structured interview
THEME Frequency
(n = 17 interviews)
DOMAIN 1: Impact of treatment
Negative emotional reactions to treatment 10
Missing school for treatment 7
Anxiety about improvement 5
Avoidance 5
Side Effects 5
Anticipatory nausea 4
Painful Injections 4
Difficulty swallowing tablets 3
DOMAIN 2: Complications
Cataract removal 6
Poor vision/blurring 6
Glaucoma surgery 3
DOMAIN 3: Impact on School
Difficulties reading information 9
Upset at missing lessons 8
Teachers forgetting 7
Anxiety about catching up with missed work 5
Difficulties seeing the ball in PE 4
Upset at missing friends/activities at school 4
DOMAIN 4: Impact outside school
Needing adaptations in order to participate 5
Not able to see bus numbers readily 4
DOMAIN 5: Social Factors
Being excluded 8
Not chosen as team member 6
Bullying 4
Self-exclusion 2
DOMAIN 6: Emotional Reactions
Distress/sadness about illness 11
Fear 9
Anger 8
Worry about deterioration 7
Worry about going blind 7
Worry about the future/careers 6
Why me? 2
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There were fewer themes identified in the “impact out-
side of school” domain. The most commonly reported
adaptations were sitting close to the television and hold-
ing hand held consoles or books close to the face. The
zoom function on many IT tablets was reported as being
very useful. Children and young people reported not be-
ing able to see the numbers on buses until they were
quite close. Occasionally activities were dropped due to
problems with eyesight which saddened young people.
In the “social factors” domain, the impact of both the
treatment and complications of uveitis ranged from not
feeling included or being the last person selected for a
team or activity, to being actively bullied:
“I was bullied every day in Year 9 [age 13-14
years]...They found out I had had eye surgery and they
called me ‘eye surgery gone wrong’. They said I was
diseased or contagious and wouldn’t go near me”.
In addition to peer rejection, self-exclusion from activities
was also reported. In older teenagers, restrictions imposed
by treatment also led to feelings of being left out, especially
when medication contraindicated alcohol consumption.
A range of almost universally negative emotional reac-
tions both to the treatment and complications of uveitis
were described. Reactions included anger, fear, embarrass-
ment, isolation and low mood.
“…when I used to go to [hospital] for my cataracts
and see the people in there and I was the youngest by
at least half a century ...it gets a bit depressing”.
Much of the anxiety and worry surrounded possible visual
deterioration and the unpredictability of the disease. Fears
about the future were apparent, especially in relation to
possible careers. Those who had identified potential ca-
reers for themselves were particularly concerned about
the impact that eyesight problems would have. Some chil-
dren and young people were explicit about their fear of
going blind:
“I am scared I am going to go blind”.
Many of the children and young people involved in the
study expressed distress, anger and resentment of the
condition. There were reports of being frustrated and
angry about the restrictions and limitations imposed by
the condition, feelings often associated with questions
about why this had happened to them. In more extreme
cases, children and young people reported feeling that
life was not worth living.
“I used to feel, well I still feel like ‘why me?’ and all
that kind of stuff, because it can feel unfair”
Discussion
Our study has identified multiple important themes
across all 6 domains. As expected, within Domain 1,
“impact of treatment”, the greatest number of themes
for any single domain were identified. The themes most
strongly represented were negative emotional reactions
to treatment, missing school for treatment, side effects
and treatment avoidance. Within Domain 2, “complications
of uveitis and treatment”, the themes most frequently
occurring were concerns regarding cataract removal and
poor vision or visual blurring.
Domain 3, “impact on school”, also highlighted several
important themes, primarily difficulties reading informa-
tion, upset at missing lessons, teachers forgetting about
their condition, anxiety about catching up with missed
work and upset at missing friends. It was also apparent
that it is more difficult for children to spend free time
catching up with subjects that they dislike, leading to
additional resentment about missed school. Further-
more, for many children and young people, school is the
main opportunity to socialise with their peers, and inter-
ruption of peer interaction was raised as an important
concern, as was re-integrating into the peer group
following periods of absence. The social importance of
school was demonstrated in several strong themes
coming from Domain 5, “social factors”, including bully-
ing, being excluded and not being chosen as a team
member. Such bullying can lead to school avoidance,
potentially further impairing the academic achievements
of a young person already regularly absent from school
due to hospital appointments and illness.
The “impact outside of school”, Domain 4, developed
fewer themes, with the requirement of adaptations in
order to participate in activities and the inability to see
bus numbers with ease being identified.
In view of the distress and difficulty apparent from the
themes discussed above, it is unsurprising perhaps that
Domain 6 “emotional reactions” produced some very
strong themes, primarily distress and sadness about the
illness, fear, anger and worry about deterioration, going
blind and the future. This implies that although specific
practical and social difficulties are problematic, the com-
bination of these issues, compounded by the frightening
nature of a vision-threatening condition, can result in a
heavy emotional burden.
The only current validated uveitis-specific QoL meas-
ure in children, the EYE-Q, comprises 19 items measur-
ing near, far, colour and night vision, photosensitivity,
and functionality. There are four QoL items enquiring
about feelings regarding the use of medications, missing
school for appointments, and “laboratory draws”. One
question enquires about the presence of common uveitis
symptoms, and there is an item that enquires about
visual aids [4]. An early version was felt to be more a
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measure of visual function than QoL, demonstrated by
EYE-Q scores being weakly associated with HRQoL
measured using the generic PedsQL tool, however the
most recent version, which included the 4 QoL questions,
shows moderate correlation with PedsQL [4, 11, 22]. The
topics include two important issues identified in Domain
1, “impact of treatment”, one from Domain 2, “complica-
tions” and one from Domain 4 “impact outside school”.
However, no themes from Domains 3, 5 or 6, “impact on
school”, “social factors” and “emotional reactions” are
covered, topics we found to be of significant concern to
children in our study.
Other tools, generic, vision and disease-specific, measur-
ing QoL in children have good coverage of these important
themes (Table 3).
The PedsQL, a validated measure of general HRQoL
in children aged 2–18 years, covers 4 core scales: phys-
ical functioning, emotional functioning, social function-
ing and school functioning, with 5 questions in each [5].
It thoroughly covers three domains we also found to be
important: “impact on school”, “social factors” and
“emotional reactions”. It is the standard against which
other QoL tools are correlated [3, 4, 11].
The Impact of Vision Impairment on Children (IVI_C)
is a 24 question, psychometrically valid vision-specific
QoL measure, for use in vision-impaired children aged 8
to 18 years who have no additional disabilities. It in-
cludes themes identified in Domains 3, 4, 5 and 6, with a
heavy emphasis on the impact on school and social func-
tioning. It has been shown to have construct, face and
content validity, as well as internal consistency and good
test re-test reliability [8, 11]. A second vision-specific in-
strument, the VQoL_CYP, is an age-appropriate, vision
related quality of life instrument for self-reporting by
children with visual impairment, consisting of a 35 item
scale [3]. It covers Domain 3 and has extensive coverage
of Domains 4 and 5, with a focus on “social factors” and
“emotional reactions” in particular. A strong correlation
between VQoL_CYP and PedsQL Total Summary Score,
particularly its psychosocial health scale has been shown.
The correlation of VQoL_CYP with the PedsQL psycho-
social summary score was found to be greater than the
moderate correlation with PedsQL physical health sum-
mary score, providing evidence for strong psychosocial
component of the VQoL_CYP [3].
A disease-specific tool, the Intermittent Exotropia
Questionnaire (ITXQ), is a 3-part, patient-derived
HRQoL questionnaire for children with intermittent
exotropia (IXT) and their parents, comprising child,
proxy and parent questionnaires with 12 questions in
each part [23]. It especially examines “emotional con-
cerns”, Domain 6, and some “social factors”, Domain 5.
Although the ITXQ was not directly compared with
another measure of HRQoL, during validity studies,
children with ITX were shown to have worse HRQoL
than controls. This finding is reinforced by previous
studies showing children with ITX had worse HRQoL
compared to controls, when measured by PedsQL [23].
A second disease-specific tool, the Quality of Life in
Children with Vernal Keratoconjunctivitis (QUICK)
questionnaire is for children aged 5 to 12 years with
chronic keratoconjunctivitis [7]. It consists of 16 items
and primarily enquires about symptoms and the social
impact of disease, Domain 5. It showed internal validity
and consistency, with significant correlations to the
KINDL, a generic instrument for assessing HRQoL in
children and adolescents aged 3 years and older and an
alternative to PedsQL [24].
This study has included patients of a variety of ages
and with a range of uveitis disease severity. Patients were
recruited through a joint Paediatric Rheumatology /
Ophthalmology clinic at a tertiary referral hospital and
those included had moderate or severe disease. The
results may not, therefore, be representative of patients
with mild, uncomplicated disease controlled with a
single agent. One included patient had Blau syndrome
with panuveitis, predominantly anterior uveitis. One of
the patients with JIA-associated uveitis had panuveitis
and another also had macular involvement (Table 1). It
is unlikely that the impact of uveitis and its treatment in
Table 3 Coverage of QoL domains by tool
Quality of Life tool
Domain EYE-Q [4] Peds-QL [5] IVI-C [8] VQoL-CYP [3] ITXQ [23] QUICK [7]
1: Impact of treatment X
2: Complications X
3: Impact on school X X X
4: Impact outside school X X X
5: Social factors X X X X X
6: Emotional reactions X X X
Legend: EYE-Q Effects of Youngsters’ Eyesight on Quality of Life Questionnaire, ITXQ Intermittent exotropia questionnaire, IVI-C Impact of Vision Impairment for
Children, PedsQL Pediatric Quality of Life Inventory, QUICK Quality of Life in Children with Vernal Keratoconjunctivitis, VQoL_CYP Vision-related Quality of Life Instrument
for Children and Young People
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the patient with Blau syndrome is very dissimilar to
those with JIA.
The study has identified themes within three domains
(“impact on school”, “social factors” and “emotional
reactions”) which are affected specifically by uveitis
disease and treatment but are not covered by the EYE-
Q. Questions which address these domains are included
in other generic and ophthalmology disease-specific
HRQoL tools for children (Table 3). In the future, it will
be important to develop uveitis-specific HRQoL tools
covering all these domains, and to include patients with
other similar diseases and healthy controls as part of the
validation process.
Clinical trials of treatments for JIA-associated uveitis
are ongoing, including APTITUDE, a phase II trial of
tocilizumab in anti-tumour necrosis factor (TNF) refrac-
tory patients [25] and studies of other biologic drugs are
likely in the coming years. HRQoL measures are increas-
ingly important as part of health economic evaluation of
novel treatments [26]. These form a critical part of the
recommendations of organisations advising health
services about clinical and cost effectiveness such as the
National Institute for Health and Care Excellence
(NICE) in the UK. Similarly, being able to demonstrate
effectiveness of treatment of JIA-associated uveitis using
not only SUN criteria but also PROMs and HRQoL will
provide additional patient-centred outcomes [27].
Conclusion
Multiple vision and disease-specific measures of HRQoL
include questions on domains that this study has shown
to be important factors influencing HRQoL in children
with chronic anterior uveitis, such as “impact on school”,
“social factors” and “emotional reactions”. This study
suggests that the inclusion of these domains should be
considered in future uveitis-specific tools examining
HRQoL in children.
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